RxDoctor Payments DataLook up a doctor →

Charles Zelen, DPM

Foot & Ankle Surgery · Roanoke, VANPI 1508837402

Payments from drug & device makers

$6,198,084in general payments, 2019–2025

Across 186 payments — averaging $33,323 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Polarityte, Inc.$2.8M
  • Musculoskeletal Transplant Foundation Inc.$1.4M
  • Misonix Inc$1.2M
  • Geistlich Pharma, North America, Inc.$544K
  • Stryker$163K
  • Biodynamik, Inc$9K
  • plus $13K from 17 others
$807,049in research payments, 2019–2025

Across 21 payments — averaging $38,431 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Geistlich Pharma, North America, Inc.$735K
  • Polarityte, Inc.$53K
  • Musculoskeletal Transplant Foundation Inc.$19K

What the payments were for

  • Consulting fees$356,00098%
  • Travel & lodging$4010%
  • Food & beverage$7,0882%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,198,084 in reported general payments places this provider in the 95th percentile of 260 foot & ankle surgery providers in Virginia.

See all foot & ankle surgery providers in Virginia

Medicare billing

Part B allowed, 2024
$59,348
Medicare patients
102
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate12$8,674
Gabapentin115$1,081
Pregabalin46$1,005
Nabumetone52$649
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen28$578
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen31$524
Duloxetine Hcl18$205
Terbinafine Hcl13$79
Meloxicam34$71

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →